长春高新(000661) - 2016 Q1 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for Q1 2016 is projected to be between 117 million and 127 million CNY, representing a year-on-year increase of 21.64% to 32.04% compared to 96.18 million CNY in the same period last year[3] - The basic earnings per share for Q1 2016 is expected to be approximately 0.94 CNY, up from 0.73 CNY per share in the previous year[3] - The increase in performance is primarily attributed to revenue growth from key pharmaceutical subsidiaries and the real estate company[5] Financial Reporting - The performance forecast has not been audited by registered accountants[4] - The financial data presented is based on preliminary calculations by the company's finance department, with detailed financial data to be disclosed in the Q1 2016 report[6] Investment Risks - Investors are advised to pay attention to investment risks associated with the performance forecast[6]